panCELLa aims to make our therapeutic cell-focused Platform Technologies widely available for the treatment of degenerative, infectious and malignant diseases.
panCELLa’s vision is to increase quality of human life.
- Strong academic research
- Extensive clinical experience
- Visionary leadership
- Broad network building capabilities
Co-founded in 2015 by Dr. Andras Nagy, PhD, stem cell biologist and Dr. Armand Keating, MD, PhD, clinical scientist and haematologist. The expertise represented by the co-founders were a perfect combination to create a unique conceptual framework for a company aiming to move cell therapy to broad clinical applications. panCELLa is a privately-held early-stage biotechnology firm based on the innovative technology developed in Dr. Andras Nagy’s lab at the Sinai Health System (SHS). panCELLa has created platforms that allow for the development of safe, universal, cost-effective, “off-the-shelf” therapeutic cell products for medicine.
panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive FailSafe(TM) and Stealth Cells(TM) and its in-licensed SAFE harbor technology. panCELLa aims to develop therapeutic products in the immunology, mesenchymal stem cell and pancreatic islet space and to partner with other companies to develop novel products in other areas of regenerative medicine. panCELLa continues its internal R&D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination and tolerization.